

Market Announcement / ASX Release

1 October 2025


Positive Developments in U.S. Cannabis Classification Signal Potential Industry Catalysts; Implications for Bioxyne's Growth Strategy

Bioxyne Limited (BXN or "Company") (ASX: BXN) is pleased to provide the following update in light of recent developments in U.S. cannabis classification, which may materially influence the global regulatory environment and investment climate for cannabinoid and psychedelic-derived therapeutics.

Key Highlights

- 1. Possible U.S. Rescheduling of Cannabis
 - Reports indicate that the Trump administration is actively considering reclassifying cannabis from a Schedule I controlled substance (highest federal restriction) to Schedule III status, which recognizes medical use and carries lower regulatory barriers.
 - Such a change could facilitate broader research access, ease banking and tax constraints, and unlock pathways for institutional investment in cannabinoid therapeutics.
 - President Trump has signalled a decision will be made in the coming weeks.
- 2. Sector Response and Market Momentum
 - Cannabis stocks and sector ETFs rallied on early announcements of reclassification, reflecting industry anticipation of a more supportive policy framework.
 - Analysts and industry commentators view rescheduling as one of the most consequential regulatory changes for the cannabis and broader alternative therapeutics sector in recent years.
- Implications for Bioxyne and Strategic Positioning
 - As a vertically integrated manufacturer of medicinal cannabis and psychedelic compounds via its wholly-owned subsidiary, Breathe Life Sciences (BLS), Bioxyne is well positioned to capitalise on easing regulations.







- The prospect of improved capital access, reduced regulatory friction, and stronger investor appetite could accelerate deployment of growth capital, expedite clinical development, and enhance cross-border opportunities.
- While U.S. reclassification does not directly change Australian regulation, positive shifts in the major U.S. market can influence global investor sentiment, regulatory discourse, and collaborative opportunities.
- Bioxyne continues to drive revenue growth, scale manufacturing capabilities, and expand its pipeline of psychedelic and cannabinoid therapeutics.

Forward Outlook & Risk Considerations

- Bioxyne emphasises that these developments remain prospective and subject to final U.S. regulatory decisions, legislative or rulemaking processes, and legal challenges.
- There is no guarantee that a final reclassification will occur, or that any such change would directly benefit all industry participants or jurisdictions.
- The Company will monitor developments closely and assess whether there are strategic partnerships, licensing, or investment opportunities that may emerge as a result.
- Bioxyne reaffirms its ongoing guidance for FY2026 (revenue and EBITDA) as previously announced, barring material changes to its operating environment.
- The Company will keep the market informed should material developments arise.

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

Bioxyne Limited Investor Relations

Email: info@bioxyne.com Phone: +61 2 9078 8180

Sam Watson

Chief Executive Officer

